Corvus Pharmaceuticals

$3.93
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-1.02%) Today
+$0.03 (+0.77%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell CRVS and other stocks, options, and ETFs commission-free!

About CRVS

Corvus Pharmaceuticals, Inc. Common Stock, also called Corvus Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA. The listed name for CRVS is Corvus Pharmaceuticals, Inc. Common Stock.

CEO
Richard A. Miller
Employees
53
Headquarters
Burlingame, California
Founded
2014
Market Cap
109.44M
Price-Earnings Ratio
Dividend Yield
Average Volume
160.07K
High Today
$3.96
Low Today
$3.88
Open Price
$3.92
Volume
57.93K
52 Week High
$6.88
52 Week Low
$1.01

Collections

CRVS Earnings

-$0.44
-$0.29
-$0.15
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 4, After Hours

You May Also Like